|
|
| | AG 1478 Basic information |
| Product Name: | AG 1478 | | Synonyms: | NSC 669364;N-[3-CHLOROPHENYL]-6,7-DIMETHOXY-4-QUINAZOLINAMINE;N-(3-CHLOROPHENYL)-N-(6,7-DIMETHOXY-4-QUINAZOLINYL)AMINE;SU 5271;WHI-P 79;TYRPHOSTIN AG 1478;TYRPHOSTIN AG 1517;AG 1478 | | CAS: | 175178-82-2 | | MF: | C16H14ClN3O2 | | MW: | 315.75 | | EINECS: | | | Product Categories: | | | Mol File: | 175178-82-2.mol |  |
| | AG 1478 Chemical Properties |
| Melting point | 180 - 183°C | | storage temp. | 2-8°C | | solubility | 0.1 M HCl: soluble <0.4 mg/mL | | form | Pale yellow solid | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| | AG 1478 Usage And Synthesis |
| Description | AG-1478 (175478-82-2; base) is a potent and selective inhibitor of the EGFR kinase (IC50 = 3 nM). Inhibits proliferation of a variety human cancer cell lines.1,2 AG-1478 reduces pulmonary fibrosis in a rat model.3?Cell permeable. | | Uses | A highly potent and specific EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. | | Uses | Tyrphostin AG 1478 is a potent and selective inhibitor of EGFR. | | Uses | Tyrphostin AG 1478 has been used as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor to study its effect on desmoid cell mobility in boyden chamber motility assays. It has also been used to inhibit phosphorylation of c-Met by exogenous transforming growth factor α in epidermoid carcinoma cell line A431. | | Definition | ChEBI: Tyrphostin AG 1478 is a member of the class of quinazolines that is quinazoline substituted by methoxy groups at positions 6 and 7 and a (3-chlorophenyl)nitrilo group at position 4. It acts as an epidermal growth factor receptor antagonist. It has a role as an epidermal growth factor receptor antagonist, an antineoplastic agent, a geroprotector and an antiviral agent. It is a member of quinazolines, an aromatic ether and a member of monochlorobenzenes. | | General Description | Highly potent and specific inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase (IC50 = 3 nM). Much higher concentrations are required for inhibition of the kinase activity of the closely related HER2 (neu/erb-B2) receptor (IC50 >100 μM), the platelet-derived growth factor (PDGF) receptor (IC50 >100 μM), and p210Bcr-Abl (IC50 >50 μM). Its mechanism of inhibition likely mimics that of the related compound, 4-(3-chloroanilino)quinazoline (CAQ), a competitive inhibitor with respect to ATP. | | Biochem/physiol Actions | Primary TargetEpidermal growth factor receptor kinase | | References | 1) Han et al. (1996), Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors; Cancer Res., 56 3859
2) Partik et al. (1999), Inhibition of epidermal-growth-factor-receptor-dependent signaling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro; J. Cancer Res. Clin. Oncol., 125 379
3) Rice et al. (1999), Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats; Am. J. Pathol., 155 213 |
| | AG 1478 Preparation Products And Raw materials |
|